ArticleJACC. Heart failure2025
Differential Associations of Cardiac, Pulmonary, Arterial, and Muscle Physiological Parameters and Biomarkers With the Incidence of HFpEF and HFrEF.
Article in JACC. Heart failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heart failure with preserved ejection fraction, from pathophysiology to technology tools aim improve patients' management.Heart failure reviews · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundPostulated differences in heart failure with preserved ejection fraction (HFpEF) compared with heart failure with reduced ejection fraction (HFrEF) include greater contributions of noncardiac dysfunction to HFpEF.
objectivesThis study aims to evaluate associations of cardiac and noncardiac physiological measures with prevalent and incident HFpEF and HFrEF.
methodsAmong 5,484 ARIC (Atherosclerosis Risk In Communities) study participants attending the fifth visit (2011-2013), this study assessed associations of cardiac structure and function by echocardiogram, pulmonary function by spirometry, arterial stiffness by pulse wave velocity, muscle strength by handgrip, fat mass by bioimpedance, inflammation by plasma biomarkers, and renal function with prevalent and incident adjudicated HFpEF (ejection fraction [EF] ≥50%) and HFrEF (EF <50%) by using adjusted logistic and Cox models.
resultsMean age was 75 ± 5 years, 59% were women, left ventricular (LV) EF was 65% ± 7%, 246 patients had prevalent HFpEF, and 81 patients had prevalent HFrEF. Worse LV and right ventricular systolic function and larger LV size were associated more strongly with prevalent HFrEF; a higher body mass index (BMI) was associated more strongly with prevalent HFpEF. Among heart failure-free participants, 220 incident HFpEF and 187 HFrEF events occurred over a median 7 years (range: 6-8 years) of follow-up. Worse LV systolic function and larger LV size were more strongly associated with incident HFrEF, whereas higher pulmonary artery systolic pressure demonstrated a greater association with incident HFpEF. Most noncardiac dysfunctions, including greater BMI, fat mass, and systemic inflammation, showed similar magnitudes of association with incident HFpEF and HFrEF.
conclusionsAmong older adults, subclinical LV systolic dysfunction and remodeling differentially predicted the risk of incident HFrEF, whereas diastolic and most noncardiac dysfunctions were associated similarly with both incident HFpEF and HFrEF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.